-
公开(公告)号：US20080305188A9
公开(公告)日：2008-12-11
申请号：US10552029
申请日：2003-04-03
IPC分类号： A61K36/489
CPC分类号： A61K36/185 , A61K36/48 , A61K36/489 , A61K2300/00
摘要： The present invention relates to a novel composition comprising geranium oil and extracts from the roots of the plants of the genus Sophora, preferably Sophora tonkinesis. Said composition can be administered to mammalian animals undergoing cancer treatments, such as chemotherapy and radiation therapy, that would induce the side effect of bone marrow suppression. The administration can be made before, during and or after the cancer treatment.
摘要翻译： 本发明涉及一种新颖的组合物，其包含天竺葵油和来自苦参属植物的根的提取物，优选苦参素（Sophora tonkinesis）。 所述组合物可以施用于经历诸如化疗和放射治疗的癌症治疗的哺乳动物，其将诱导骨髓抑制的副作用。 可以在癌症治疗之前，期间和之后进行给药。
-
公开(公告)号：US20070166404A1
公开(公告)日：2007-07-19
申请号：US10552029
申请日：2003-04-03
IPC分类号： A61K36/489
CPC分类号： A61K36/185 , A61K36/48 , A61K36/489 , A61K2300/00
摘要： The present invention relates to a novel composition comprising geranium oil and extracts from the roots of the plants of the genus Sophora, preferably Sophora tonkinesis. Said composition can be administered to mammalian animals undergoing cancer treatments, such as chemotherapy and radiation therapy, that would induce the side effect of bone marrow suppression. The administration can be made before, during and or after the cancer treatment.
摘要翻译： 本发明涉及一种新颖的组合物，其包含天竺葵油和来自苦参属植物的根的提取物，优选苦参素（Sophora tonkinesis）。 所述组合物可以施用于经历诸如化疗和放射治疗的癌症治疗的哺乳动物，其将诱导骨髓抑制的副作用。 可以在癌症治疗之前，期间和之后进行给药。
-
公开(公告)号：US20080119567A1
公开(公告)日：2008-05-22
申请号：US11984617
申请日：2007-11-20
IPC分类号： A61K31/045 , A61P31/04
CPC分类号： A61K9/08 , A23K20/105 , A23K50/00 , A23K50/50 , A23L33/105 , A23V2002/00 , A61K9/0019 , A61K9/0095 , A61K9/4825 , A61K36/185 , A61K36/48 , A61K36/489 , A61K47/26 , A61K2300/00 , A23V2200/32 , A23V2250/21
摘要： The present invention relates to herbal composition and methods of administering an herbal composition, comprising geranium oil and extracts from roots of the plants of the genus Sophora, particularly S. flavescenes and S. tonkinensis, to humans and other mammalian animals with gastric ulcers induced by H. pylori infection. The same composition is shown to be able to eradicate H. pylori in vitro. The invention also relates to a composition comprising citronellol and extracts from roots of Sophora plants. The present invention further relates to the use of citronellol to inhibit gastric ulcers. The invention also relates to the use of the same composition to inhibit the enzymatic activity of Na+/K+-ATPase to strengthen heart muscle contractions and prevent heart failure.
摘要翻译： 本发明涉及草药组合物和施用草药组合物的方法，所述草药组合物包含天竺葵油和从所述苦参属植物的根中提取的提取物，特别是S.flavescenes和S.tonkinensis，给人类和其他哺乳动物带有由胃溃疡引起的胃溃疡 幽门螺杆菌感染。 相同的组合物显示能够在体外根除幽门螺杆菌。 本发明还涉及包含香茅醇和来自苦参植物根的提取物的组合物。 本发明还涉及香茅醇抑制胃溃疡的用途。 本发明还涉及相同组合物用于抑制Na + + / K + + ATP酶促酶活性以增强心肌收缩和预防心力衰竭的用途。
-
公开(公告)号：US07507532B2
公开(公告)日：2009-03-24
申请号：US11074129
申请日：2005-03-07
申请人： Stanley Chang , Hsun-Lang Chang , Wei-Ying Kuo , Kuo-Yen Chen , Ning-Yi Li , Chih-Ping Hsu , Pei-Hsun Ho
发明人： Stanley Chang , Hsun-Lang Chang , Wei-Ying Kuo , Kuo-Yen Chen , Ning-Yi Li , Chih-Ping Hsu , Pei-Hsun Ho
IPC分类号： C12Q1/68
CPC分类号： G01N33/5748 , C07K16/30 , C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158
摘要： MH15 (Hn1L) is identified as an oncogene. Methods and compositions for detecting and diagnosing cancer in patients are provided, by determining the level of MH15 expression in biological samples. Also provided are methods for screening for inhibitors and moderators of MH15 expression and activity, as well as compositions comprising compounds and molecules that inhibit or moderate MH15 expression or activity, thereby treating cancer, in vivo.
摘要翻译： MH15（Hn1L）被鉴定为癌基因。 通过确定生物样品中MH15表达的水平，提供了检测和诊断患者癌症的方法和组合物。 还提供了用于筛选MH15表达和活性的抑制剂和调节剂的方法，以及包含抑制或抑制MH15表达或活性，从而在体内治疗癌症的化合物和分子的组合物。
-
公开(公告)号：US20050153352A1
公开(公告)日：2005-07-14
申请号：US11031922
申请日：2005-01-07
申请人： Stanley Chang , Hsun-Lang Chang , Wei-Ying Kuo , Kuo-Yen Chen , Ning-Yi Li
发明人： Stanley Chang , Hsun-Lang Chang , Wei-Ying Kuo , Kuo-Yen Chen , Ning-Yi Li
CPC分类号： C07H21/04 , C07K16/32 , C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/156 , C12Q2600/178 , G01N33/57484
摘要： MG20 (CCNDBP1) is identified as an oncogene. Methods and compositions for detecting and diagnosing cancer in patients are provided, by determining the level of MG20 expression in biological samples. Also provided are methods for screening for inhibitors and moderators of MG20 expression and activity, as well as compositions comprising compounds and molecules that inhibit or moderate MG20 expression or activity, thereby treating cancer, in vivo.
摘要翻译： MG20（CCNDBP1）被鉴定为癌基因。 通过确定生物样品中MG20表达的水平，提供了检测和诊断患者癌症的方法和组合物。 还提供了用于筛选MG20表达和活性的抑制剂和调节剂的方法，以及包含抑制或缓和MG20表达或活性，从而在体内治疗癌症的化合物和分子的组合物。
-
公开(公告)号：US20060068411A1
公开(公告)日：2006-03-30
申请号：US11074129
申请日：2005-03-07
申请人： Stanley Chang , Hsun-Lang Chang , Wei-Ying Kuo , Kuo-Yen Chen , Ning-Yi Li , Chih-Ping Hsu , Pei-Hsun Ho
发明人： Stanley Chang , Hsun-Lang Chang , Wei-Ying Kuo , Kuo-Yen Chen , Ning-Yi Li , Chih-Ping Hsu , Pei-Hsun Ho
IPC分类号： C12Q1/68 , G01N33/574
CPC分类号： G01N33/5748 , C07K16/30 , C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158
摘要： MH15 (Hn1L) is identified as an oncogene. Methods and compositions for detecting and diagnosing cancer in patients are provided, by determining the level of MH15 expression in biological samples. Also provided are methods for screening for inhibitors and moderators of MH15 expression and activity, as well as compositions comprising compounds and molecules that inhibit or moderate MH15 expression or activity, thereby treating cancer, in vivo.
-
公开(公告)号：US20080020386A1
公开(公告)日：2008-01-24
申请号：US11692565
申请日：2007-03-28
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/16 , C12Q2600/172
摘要： A method for determining the human leukocyte antigen (HLA) genotype of a nucleic acid sample, comprises: contacting a nucleic acid sample with at least one nucleic acid primer set and subjecting the mixture to a nucleic acid amplification reaction; determining the size of any amplification products produced in the amplification reaction; and correlating the presence and/or absence of specific amplification products with the presence and/or absence of specific sequence polymorphisms in the nucleic acid sample. At least one of the primer sets is a multi-specific primer set comprising at least one sequence-specific forward primer and at least one sequence-specific reverse primer and being adapted to amplify two or more specific target sequences in the nucleic acid sample. Each of the specific target sequences comprises a sequence polymorphism that is known to be associated with an HLA allele and which may be present in the nucleic acid sample to be genotyped.
摘要翻译： 用于确定核酸样品的人白细胞抗原（HLA）基因型的方法包括：使核酸样品与至少一个核酸引物组接触，并使混合物进行核酸扩增反应; 确定在扩增反应中产生的任何扩增产物的大小; 并将特异性扩增产物的存在和/或不存在与核酸样品中特异性序列多态性的存在和/或不存在相关联。 引物组中的至少一个是包含至少一个序列特异性正向引物和至少一个序列特异性反向引物并适于扩增核酸样品中两个或多个特异性靶序列的多特异性引物组。 每个特定靶序列包含已知与HLA等位基因相关并且可存在于待基因型的核酸样品中的序列多态性。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.03 秒)
